Pharmaceutical Manufacturers Testing Use of Verification Router Services To Process Saleable Returns Under DSCSA
Executive Summary
Pharmaceutical manufacturers, distributors and wholesalers are piloting the use of verification router service (VRS) systems to comply with a looming deadline under DSCSA requiring them to establish systems for verifying saleable returns. Yet there are still many unanswered questions on how these systems will work.
You may also be interested in...
FDA Gives Wholesalers One-Year Breather From Saleable Returns Verification
As expected, the FDA will not take enforcement action against wholesalers that are unable to comply with DSCSA’s saleable return verification requirements by the 27 November deadline.
GS1 Standard Would Speed The Sale Of Returned Drugs After November Deadline
New messaging standard from GS1 would enable industry to sell most returned drugs after November DSCSA deadline without running afoul of the FDA.
FDA Outlines Systems Manufacturers Should Have In Place For Handling Suspect Drugs Under DSCSA
Manufacturers need to have robust verification processes in place and actively communicate with their trading partners to handle suspect drugs that are not properly serialized under DSCA, FDA draft guidance document says.